Profiling serum oxylipin metabolites across melanoma subtypes and immunotherapy responders
Preprint
Abstract
Objectives: This study investigates the relationship between serum oxylipin profiles and response to immune checkpoint inhibitor therapy in melanoma subtypes to identify potential metabolic biomarkers for treatment response. Methods: In a retrospective cohort study, serum samples from 43 stage III and stage IV melanoma patients treated at the University of Colorado Hospital from 2010 to 2023 were analyzed via ultra-high-pressure liquid chromatography-mass spectrometry. Melanoma patients were treated anti-PD-1 monotherapy or combination immune checkpoint inhibitor therapy and response was assessed using RECIST 1.1 criteria. Results: Using mass spectroscopy, we determined global oxylipin metabolite profiles are largely uniform pre-and post-treatment across melanoma subtypes including cutaneous, acral, mucosal, and uveal melanoma. Across subtypes, 33 oxylipin metabolites were analyzed, with limited variation observed overall. Prostaglandin J 2 was more abundant in rare melanoma subtypes including acral, mucosal, and uveal melanoma compared to cutaneous melanoma. Conclusions: Despite limited variation of serum oxylipin molecular species by subtype and response status, we observed significant differences in Prostaglandin J 2 which could serve as a potential biomarker for immune checkpoint inhibitor therapy response in melanoma. However, further investigation is warranted to explore the role of oxylipins in immune response modulation.Keywords
All Related Versions
- Published version: Metabolites, 16 (1), 14.
This publication has 25 references indexed in Scilit:
- Untargeted and Semi-targeted Lipid Analysis of Biological Samples Using Mass Spectrometry-Based Metabolomics2019
- Genistein reduces proliferation of EP3-expressing melanoma cells through inhibition of PGE2-induced IL-8 expressionInternational Immunopharmacology, 2018
- Role of prostaglandins in tumor microenvironmentCancer and Metastasis Reviews, 2018
- Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative StressCancer Cell, 2018
- EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunityOncoImmunology, 2017
- A three‐minute method for high‐throughput quantitative metabolomics and quantitative tracing experiments of central carbon and nitrogen pathwaysRapid Communications in Mass Spectrometry, 2017
- The efficacy of anti‐PD‐1 agents in acral and mucosal melanomaCancer, 2016
- Oncolytic Virus-Mediated Targeting of PGE 2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to ImmunotherapyCancer Cell, 2016
- Pro-resolving lipid mediators are leads for resolution physiologyNature, 2014
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009